![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ACT, Toray Sign Agreement on Innovative Catheter Technology
ACT, Toray Sign Agreement on Innovative Catheter Technology
![Signing](https://www.fdanews.com/ext/resources/test/Drug-Images/signing.jpg?t=1620076341&width=430)
April 19, 2016
Advanced Catheter Therapies and Toray Industries have inked a license agreement to manufacture, market and sell Occlusion Perfusion Catheter.
The FDA-cleared OPC is a targeted therapeutic agent delivery system for peripheral vascular stenosis and restenosis.
The OPC is a multi-lumen balloon catheter designed to provide targeted delivery — creating a localized treatment chamber — of various therapeutic and diagnostic agents to the peripheral and coronary vasculature by temporarily occluding a specific region from blood flow. — Joya Patel
Upcoming Events
-
21Oct